Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1454 ARTÍCULOS , VIENDO DEL 346 AL 360

Targeting TNF: a therapeutic strategy for Alzheimer's disease

Cheng X, Shen Y, Li R.

Drug Discov Today. 2014 Nov;19(11):1822-1827. doi: 10.1016/j.drudis.2014.06.029. Epub 2014 Jul 4.

Interaction of Alzheimer's β-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation

Di Scala C, Chahinian H, Yahi N, Garmy N, Fantini J.

Biochemistry. 2014 Jul 22;53(28):4489-502. doi: 10.1021/bi500373k. Epub 2014 Jul 11.

Statins for the treatment of dementia

McGuinness B, Craig D, Bullock R, Malouf R, Passmore P.

Cochrane Database Syst Rev. 2014 Jul 8;2014(7):CD007514. doi: 10.1002/14651858.CD007514.pub3.

ITH12410/SC058: a new neuroprotective compound with potential in the treatment of Alzheimer's disease

Romero A, Egea J, González-Muñoz GC, Martín de Saavedra MD, del Barrio L, Rodríguez-Franco MI, Conde S, López MG, Villarroya M, de los Ríos C.

ACS Chem Neurosci. 2014 Sep 17;5(9):770-5. doi: 10.1021/cn500131t. Epub 2014 Jul 15.

Deciphering an interplay of proteins associated with amyloid β 1-42 peptide and molecular mechanisms of Alzheimer's disease

Hernández-Zimbrón LF, Rivas-Arancibia S.

Rev Neurosci. 2014;25(6):773-83. doi: 10.1515/revneuro-2014-0025.

Ribonucleoprotein therapy in Alzheimer's disease?

Yoon JH, Gorospe M.

Aging (Albany NY). 2014 Jun;6(6):428-9. doi: 10.18632/aging.100672.

Health-related quality of life and self-efficacy of managing behavior problems for family caregivers of vascular dementia and Alzheimer's disease patients

Kuo LM, Huang HL, Hsu WC, Shyu YI.

Dement Geriatr Cogn Disord. 2014;38(5-6):310-20. doi: 10.1159/000360414. Epub 2014 Jul 9.

A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia

Haig GM, Pritchett Y, Meier A, Othman AA, Hall C, Gault LM, Lenz RA.

J Alzheimers Dis. 2014;42(3):959-71. doi: 10.3233/JAD-140291.

Cholinesterase inhibitors: cardioprotection in Alzheimer's disease

Monacelli F, Rosa G.

J Alzheimers Dis. 2014;42(4):1071-7. doi: 10.3233/JAD-141089.

Fibroblast aggregation rate converges with validated peripheral biomarkers for Alzheimer's disease

Chirila FV, Khan TK, Alkon DL.

J Alzheimers Dis. 2014;42(4):1279-94. doi: 10.3233/JAD-140672.

Alzheimer's disease costs: what we know and what we should take into account

Colucci L, Bosco M, Fasanaro AM, Gaeta GL, Ricci G, Amenta F.

J Alzheimers Dis. 2014;42(4):1311-24. doi: 10.3233/JAD-131556.

The effect of neuropeptide Y on cell survival and neurotrophin expression in in-vitro models of Alzheimer's disease

Angelucci F, Gelfo F, Fiore M, Croce N, Mathé AA, Bernardini S, Caltagirone C.

Can J Physiol Pharmacol. 2014 Aug;92(8):621-30. doi: 10.1139/cjpp-2014-0099. Epub 2014 Jun 13.

Alzheimer's disease--a panorama glimpse

Zhao LN, Lu L, Chew LY, Mu Y.

Int J Mol Sci. 2014 Jul 16;15(7):12631-50. doi: 10.3390/ijms150712631.

Designing in vitro strategies and in vivo models for Alzheimer's disease - promises & challenges

Kumaraswamy P, Sethuraman S, Krishnan UM.

Curr Alzheimer Res. 2014;11(6):588-607. doi: 10.2174/156720501106140711122129.

Diverse molecular targets for therapeutic strategies in Alzheimer's disease

Han SH, Mook-Jung I.

J Korean Med Sci. 2014 Jul;29(7):893-902. doi: 10.3346/jkms.2014.29.7.893. Epub 2014 Jul 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias